Sentences with phrase «other study drugs»

Parents need to open a discussion about Adderall and other study drugs.

Not exact matches

A new government - funded study suggests that addictive opioid painkillers may not be better than other, non-opioid kinds of drugs for treating chronic back pain and arthritis.

Bristol - Myers emphasized Opdivo's other successes and ongoing studies evaluating its effectiveness in combination with the company's other cancer drugs.

Other charities that have benefited from the organization include healthcare outsourcing platform Watsi; The Water Project; the Electronic Frontier Foundation digital - rights activism group; MAPS, an organization that studies therapeutic uses of psychedelic drugs and marijuana; the medical nonprofit SENS Research Foundation; and charity: water.

But according to the Government Accountability Office (GAO) which did a study in 2013 on the drug shortage, other reasons include a lack of materials to make the drugs, as well as delays in getting government approval for new and experimental drugs.

The DEA will now conduct its own eight - factor analysis to study the drug's potential for abuse, the current state of medical and scientific knowledge, the history and pattern of abuse, and other considerations.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SDrug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the Sdrug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

According to Living Goods, clients may also be reluctant to buy drugs from other private providers because of the risk of getting a counterfeit medicine.63 Living Goods sent us a study conducted at the midline of its RCT that claims that both availability of counterfeit drugs and drug prices decreased at private retailers in areas where CHPs worked.64 According to the study, about 37 % of private drug shops in the areas it studied sold fake ACT drugs, 65 and availabilty of fake ACTs was about 50 % lower among non-Living Goods sellers in the areas where Living Goods worked.66 Additional results on these potential effects will be made available when the full RCT is published.

Potential subjects were accepted into the study if they had none of the following conditions: severe or symptomatic cardiac disease or hypertension; history of bleeding disorders; chronic history of gastric, intestinal, liver, pancreatic, or renal disease; any portion of the stomach or the intestine removed (other than an appendectomy); history of intestinal obstruction, malabsorption, or use of antacid drugs; cancer (active or use of medications for a history of cancer treatment within the past 5 y); history of chronic alcoholism; a convulsive disorder; or abnormal results in screening blood or urine samples.

Students would buy the attention - deficit drugs from other students with an ADHD diagnosis before AP Exams, research papers or SAT / ACT tests, in hope of increased concentration and a greater ability to stay awake during studying.

Other studies show children who have limits and rules enforced reasonably, are less likely to get involved in drugs and juvenile crime, whereas children raised by authoritarian, harsh parenting or overly permissive parenting, had a higher risk.

ACEs usually refers to the 10 types of childhood adversity that were measured in the U.S. Centers for Disease Control and Prevention's Adverse Childhood Experiences (ACE) Study: physical abuse, emotional abuse, sexual abuse, physical neglect, emotional neglect, a family member who's an alcoholic or addicted to other drugs, a family member diagnosed with a mental illness, witnessing a mother being abused, a family member in prison, and loss of a parent through separation or divorce.

Many studies have shown that weed is often laced with other drugs.

If however many MDs aren't practicing evidence - based medicine, then why not don't MDs * police their own * before going off on other professions for their lack of evidence - base... or attacking what evidence - base there is even if it isn't multiple double - blind placebo controlled studies funded by wealthy drug manufacturers?

Other studies have shown that children with involved fathers are less likely to do drugs or drink alcohol, will be more emotionally secure, and have better social interaction with their peers.

The Journal of the American Academy of Pediatrics released a study in April of 2010 detailing just what that one medicine / vitamin / herbal supplement is... and the «miracle drug» is none other than BREASTFEEDING.

They also took into account mother's age, the baby's birth weight, the position the baby was last left in and other important factors, but they only had the data on the mother's alcohol and illegal drug usage for two of the five studies — a pretty significant limitation to the overall analysis.

For the purposes of this economic evaluation, the forms were initially used in a related study funded by the National Institute of Health Research (NIHR) research for patient benefit programme «assessing the impact of a new birth centre on choice and outcome of maternity care in an inner city area,» which will be reported in full elsewhere, comparing the costs of care in a free standing midwifery unit with care in an obstetric unit in the same trust.16 The data collected included details of staffing levels, treatments, surgeries, diagnostic imaging tests, scans, drugs, and other resource inputs associated with each stage of the pathway through intrapartum and after birth care.

The Food and Drug Administration has long permitted its use, but in recent years concerns about the chemical have grown as studies have indicated low doses of the substance can disrupt hormone systems in laboratory animals and possibly increase the risk of cancer or other serious illness.

And while the science may be disputed, depending on who is funding the study, as to whether commonly used food dyes such as Yellow 5, Red 40 and 6 others made from petroleum pose a «rainbow of risks» that include hyperactivity in children, cancer (in animal studies), and allergic reactions, because of the problem of hyperactivity, the Center for Science in the Public Interest petitioned the Food and Drug Administration to ban the use of these dyes given that the British government and European Unionhave taken actions that are virtually ending their use of dyes throughout Europe.

In controlled drug studies, some study participants receive the drug under testing; others get a placebo, which is like a sugar pill that has none of the drug being texted.

For all women included in the study, we collected data on their age, height, weight before pregnancy, body mass index, income quintile, drug and alcohol use (v. no use) during pregnancy, smoking status, status of parenthood (single v. other), parity, gestational age at first prenatal visit, number of antenatal visits and history of ultrasonography before 20 weeks» gestation.

And I only used the word «drugs» as a general term in my post, avoiding the reference to marijuana in particular because as many studies have found recently, it may very well have other valid medical uses.

«We could apply the strategy used in this study to quickly identify and design small molecule drugs for other RNA - associated diseases,» explained study first author Sai Velagapudi, a research associate in the Disney lab.

«Study debunks fears of increased teen suicide risk from popular flu drug: Other side effects remain a concern.»

Moreover, the findings, if replicated in his and others» ongoing studies, could spur development of drugs that target HDL subclasses, working to raise HDL without apoC - III and lower HDL with it.

Two recent large studies reflect growing evidence that ADHD increases children's risk for abusing tobacco, alcohol and other drugs when they are older.

The FDA recently okayed the first therapeutic cancer vaccine, and other drugs that enlist the immune system against tumors are under study

With this kind of review process, if 20 studies of the effectiveness of a truly ineffective drug are conducted, and one of them shows a significant effect with a p - value of 0.05 because of chance alone, investigators for the other 19 studies not showing any effect would presumably not be inhibited from writing up and submitting reports of these for publication out of fear that they'll be denied publication because of their nonsignificant results.

For this study the researchers targeted very specific types of GABA receptors to improve social behaviors with clonazepam, but the team also found that by using a different drug, they could target other GABA receptors and actually reduce the ability to socially interact in normal mice — underscoring that future medications would need to target very specific receptors so as not to diminish the drug's impacts.

People with drug addictions who started opioid abuse later in life use injections for their drugs, or increased their use of downers before starting drug treatment, are more likely to relapse from treatment than others, says a new study from McMaster University.

Studies of the drug abroad have shown that it is effective and has fewer side effects compared to other corticosteroids, namely less associated weight gain.

In the heady postwar years, hundreds of promising studies were conducted in the United States, Canada, and Europe on the use of LSD and other psychedelics, like peyote, to treat such psychiatric maladies as schizophrenia, autism, drug addiction, alcoholism, and chronic depression.

«Some drug addicts more likely to relapse than others: Study.»

After controlling for other factors, a generic drug in the highest marketing competition group was expected to see a decrease of 32 percent in price over the study period, while a generic drug in the lowest market competition was expected to see a price increase of 47 percent over the same period.

Two major studies published within about a week of each other suggest that the drugs do not work for these conditions.

Dr. McCabe said nanoparticles are a leading - edge technology also being studied for delivery of drugs for other conditions, such as cancer, heart disease, and bacterial infections, in order to target specific cells to reduce toxicity and side effects of those medications and to make them more effective.

Preliminary results of the study were presented at a World Health Organization (WHO) evidence review group meeting, while UNITAID has issued a call for further research into the use of endectocide class drugs, of which ivermectin is currently the only one registered for human use, as new vector control tools in the fight against malaria and other mosquito borne disease.

SapC - DOPS (saposin - C dioleoylphosphatidylserine), is a nanovesicle drug that has shown activity in glioblastoma, pancreatic cancer and other solid tumors in preclinical studies.

Some methods may be good at providing positive evidence that a drug works, for example, but other types of studies may be better at finding evidence that it doesn't — or that it also causes unacceptable side effects.

Other studies found no benefit from taking the drug.

The drug was not associated with severe toxicity in this or other recent studies.

In the current study, Frank Longo, MD, PhD, and others at Stanford University, tested LM22A - 4, a drug that specifically binds to and activates the BDNF receptor TrkB on nerve cells, in mice that model the disorder.

In animal studies this sharply reduces cravings and halts addicted animals» tendency to self - administer cocaine and other habit - forming drugs.

Other studies suggest that nicotine may be as effective at enhancing attention as methylphenidate (Ritalin) and the wakefulness - promoting drug modafinil (Provigil).

The findings support other recent rodent studies that showed drugs that enhance the action of BDNF can reduce brain changes and symptoms of Huntington's disease.

During imaging studies probing the causes of addiction, the insula often was activated when drug abusers were shown movies of others taking drugs or shown pictures of cocaine, heroin or nicotine.

The new drugs offer the hope of treatment to perhaps thousands of HIV patients who have stopped responding to other medications, says William Towner, medical director of the Kaiser Permanente HIV / AIDS research trials program and member of the study team, which reported its findings online today in The Lancet.

Currently, Deng's laboratory is conducting additional preclinical studies using the human - derived stem cells from Down syndrome patients and mouse models to determine whether cellular and behavioral abnormalities can be improved with minocycline therapy and other candidate drugs.

Currently there are no registries of egg donors in the UK or in the US, and there are only a few long - term follow up studies on egg donors who have received fertility drugs to help others.